SYMLIN

pharmaceutical preparations containing as an active ingredient an amylin agonist compound, namely, pramlintide for the treatment of fuel metabolism disorders including diabetes and obesity, osteopenia, pain, gastritis, pancreatitis, and gastric motility disorders